These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22030444)

  • 1. Influence of hepatic impairment on the pharmacokinetics and safety profile of dapagliflozin: an open-label, parallel-group, single-dose study.
    Kasichayanula S; Liu X; Zhang W; Pfister M; LaCreta FP; Boulton DW
    Clin Ther; 2011 Nov; 33(11):1798-808. PubMed ID: 22030444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Hepatic Impairment on the Pharmacokinetic Profile and Safety of Lobeglitazone.
    Park J; Kim CO; Oh ES; Lee JI; Kim JK; Ahn SH; Kim DY; Kim SU; Kim BK; Chung YE; Kim SM; Park MS
    Clin Pharmacol Drug Dev; 2022 May; 11(5):576-584. PubMed ID: 35255191
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects.
    Flanagan S; Ong V; Marbury T; Jandourek A; Gandhi RG; Sandison T
    Pharmacotherapy; 2024 Jun; 44(6):435-443. PubMed ID: 38840536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
    Zahir H; Greenberg J; Hsu C; Marbury TC; Lasseter KC; Xu LA; Tap WD; Healey JH; Stacchiotti S; LaCreta F
    J Clin Pharmacol; 2022 Aug; 62(8):992-1005. PubMed ID: 35247274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Hepatic Impairment on the Pharmacokinetics of Fenfluramine and Norfenfluramine.
    Mittur A; Madanick R; Langlois M; Boyd B
    J Clin Pharmacol; 2024 Jul; 64(7):887-898. PubMed ID: 38523492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
    Qosa H; de Oliveira CHMC; Cizza G; Lawitz EJ; Colletti N; Wetherington J; Charles ED; Tirucherai GS
    Clin Transl Sci; 2023 Oct; 16(10):1791-1802. PubMed ID: 37654022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment.
    Kallend D; Stoekenbroek R; He Y; Smith PF; Wijngaard P
    J Clin Lipidol; 2022; 16(2):208-219. PubMed ID: 35168913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the Pharmacokinetics and Safety of a Single Dose of Acalabrutinib in Subjects With Hepatic Impairment.
    Xu Y; Izumi R; Nguyen H; Kwan A; Kuo H; Madere J; Slatter JG; Podoll T; Vishwanathan K; Marbury T; Smith W; Preston RA; Sharma S; Ware JA
    J Clin Pharmacol; 2022 Jun; 62(6):812-822. PubMed ID: 34897701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1 pharmacokinetic and safety study of soticlestat in participants with mild or moderate hepatic impairment or normal hepatic function.
    Yin W; Mitra P; Copalu V; Marbury TC; Rondon JC; Lawitz EJ; Lloyd V; Baratta M; Asgharnejad M; Hui T; Khan Y
    Pharmacol Res Perspect; 2024 Aug; 12(4):e1213. PubMed ID: 38993008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy Subjects.
    Cheng Y; Ye Y; Gaudy A; Ghosh A; Xue Y; Wang A; Zhou S; Li Y
    Clin Pharmacol; 2023; 15():9-19. PubMed ID: 36880014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Multiple Doses of Sparsentan on the Single-Dose Pharmacokinetics of Dapagliflozin: An Open-Label Drug-Drug Interaction Study in Healthy Adults.
    Chen SC; Cai D; Winnett C; Nguyen M; Verma N; Liu K; Preciado P
    Clin Pharmacol Drug Dev; 2023 May; 12(5):535-541. PubMed ID: 36852566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist.
    Younis IR; Hsueh CH; Nelson C; Billin AN; Yue MS; Xiao D; Watkins TR; Othman AA
    J Clin Pharmacol; 2023 Sep; 63(9):1017-1025. PubMed ID: 37128693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.
    Kim HC; Lee S; Sung S; Kim E; Jang IJ; Chung JY
    Drug Des Devel Ther; 2023; 17():1203-1210. PubMed ID: 37113469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of mild or moderate hepatic impairment on the pharmacokinetics of risdiplam.
    Kletzl H; Ajmi H; Antys I; Heinig K; Jaber B; Marbury TC; Young A; Günther A
    Br J Clin Pharmacol; 2022 Aug; 88(8):3749-3759. PubMed ID: 35301746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study.
    Song I; Chen G; Wu J; Ilic K
    J Clin Pharmacol; 2023 Feb; 63(2):250-258. PubMed ID: 36089648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring the Impact of Hepatic Impairment on Pralsetinib Pharmacokinetics.
    Cheung KWK; Tang Y; Anders D; Barata T; Scalori A; Agarwal P; Sane R; Cheeti S
    Pharmaceutics; 2024 Apr; 16(4):. PubMed ID: 38675225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Hepatic Impairment on Trilaciclib Pharmacokinetics.
    Li C; Preston RA; Dumas E; Beelen A; Marbury TC
    J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38639103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of gender, age, diabetes mellitus and renal and hepatic impairment on tadalafil pharmacokinetics.
    Forgue ST; Phillips DL; Bedding AW; Payne CD; Jewell H; Patterson BE; Wrishko RE; Mitchell MI
    Br J Clin Pharmacol; 2007 Jan; 63(1):24-35. PubMed ID: 16869816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.
    Tortorici MA; Toh M; Rahavendran SV; Labadie RR; Alvey CW; Marbury T; Fuentes E; Green M; Ni G; Hee B; Pithavala YK
    Invest New Drugs; 2011 Dec; 29(6):1370-80. PubMed ID: 20596748
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Pharmacokinetics of Solithromycin in Subjects with Hepatic Impairment.
    Jamieson BD; Ciric S; Fernandes P
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4379-86. PubMed ID: 25870056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.